Kairos Pharma (KAPA) Interest & Investment Income (2025)
Kairos Pharma's (KAPA) quarterly Interest & Investment Income came in at $34000.0 in Q2 2025, up 750.0% quarter-over-quarter from $4000.0 in Q1 2025.
Powered by 
Analysis
Kairos Pharma (KAPA) Interest & Investment Income (2025) Analysis & Trends
Kairos Pharma (KAPA) has reported Interest & Investment Income for 1 consecutive years, with $34000.0 the latest figure, recorded in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Kairos Pharma | 31.79 Mn | 26.45 Mn | - | - |